Evija world tour continues as Lotus premieres in the Middle East

The Evija’s arrival in the Gulf states is the latest leg of a world tour which began after the car was unveiled in London on July 16.
Updated 23 September 2019

Evija world tour continues as Lotus premieres in the Middle East

The new Lotus Evija hypercar has made its debut in the Middle East at a series of exclusive media and VIP events.

The covers came off at an unveiling at the Lotus Dubai retail outlet, with Phil Popham, CEO, Lotus Cars, and Russell Carr, director, Lotus Design, presenting the all-electric two-seater to invited guests. They were joined by Karl Hamer, CEO of Adamas Motors, Lotus’ retail partner in the UAE, plus other members of senior management from both companies.

CEO Popham said: “It’s fantastic to be back in the UAE, and even better to be here as the Evija hypercar makes its regional debut. The Middle East is well-known for its passion for performance models, and this is an important market as we grow the Lotus brand significantly with new products.”

He added: “We believe the Evija will really appeal to Gulf state customers, and we’re developing the car with them — and particularly the local climate — in mind. Real-world testing of prototype vehicles is now underway to ensure optimum performance in every market.”

Hamer said: “We are delighted that our customers have the opportunity to view the Evija in the UAE so soon after its global reveal. We are proud to be in one of the most forward-thinking countries in the world, and this all-electric hypercar coming to the UAE supports our nation’s objective to focus on sustainable technologies.”

Opened a year ago, Lotus Dubai is on the emirate’s Sheikh Zayed Road. It is a 5,000 square feet state-of-the-art facility capable of showcasing up to 10 models from the Lotus performance car range. The Evija will also appear at Lotus Cars Abu Dhabi — in Sheikha Salama Building, Zayed The First Street, Al-Khalidiyah — then complete a program of private viewings.

“A technical tour de force, the Evija is illustrative of the innovative thinking and ingenuity that has always been part of the Lotus DNA. With a target output of 2000 PS, it is the world’s most powerful series production road car,” the automaker said.

The car has been designed and engineered in the UK, and will be produced at Hethel, UK, the home of Lotus since 1966, starting next year. Exclusivity is guaranteed, with production limited to a maximum of 130 cars. 

The Evija’s arrival in the Gulf states is the latest leg of a world tour which began after the car was unveiled in London on July 16. It has already included Monterey Car Week in the US and Japan Lotus Day.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.